Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics (IOVA) filed a Form S-8 to register an additional 1,000,000 shares of common stock for its 2020 Employee Stock Purchase Plan, which was amended on June 10, 2025. The shares are the same class as those previously registered for this plan.
The filing incorporates by reference earlier S-8 registrations related to the ESPP and includes customary exhibits, including the legal opinion and auditor consent.
Iovance Biotherapeutics filed its Q3 2025 10‑Q, reporting total revenue of $67.455 million and a net loss of $91.253 million. Year to date, revenue reached $176.731 million as Amtagvi and Proleukin sales scaled.
Operating costs remained heavy: cost of sales $38.477 million, R&D $75.174 million, SG&A $34.555 million, plus $5.143 million in restructuring charges, driving a loss from operations of $94.901 million. Cash used in operations for the first nine months was $249.843 million.
Liquidity was supported by $306.8 million in cash, cash equivalents, short‑term investments, and restricted cash as of September 30, 2025, and the company states it has sufficient capital to fund planned operations for at least the next twelve months. Shares outstanding were 396,967,970 as of October 15, 2025.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics (IOVA), reported transactions dated 09/02/2025 on a Form 4. The filing shows 52,086 shares of common stock acquired upon RSU vesting at no cash price and 22,127 shares withheld by the issuer to satisfy mandatory tax withholding at a reported withholding price of $2.19 per share. After these transactions the filing reports 456,690 shares beneficially owned following the vesting event and 434,563 shares remaining after the tax-withholding deduction. The filing also details newly vested restricted stock units (RSUs): 10,417 and 41,669, with resulting beneficial ownership figures shown in the form.
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reported transactions on 09/02/2025 related to restricted stock units (RSUs). On that date 5,470 RSUs vested and were converted into shares, and the issuer withheld 2,467 shares to satisfy mandatory tax withholding. After these transactions the reporting person beneficially owned 212,857 shares (the filing shows 215,324 before withholding). The filing also discloses that 32,817 RSUs remain outstanding from the March 1, 2024 grant and remaining RSUs will vest in equal quarterly installments.
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported changes in beneficial ownership on 09/02/2025. On that date 12,697 shares of common stock were acquired upon vesting of restricted stock units (RSUs). To satisfy mandatory tax withholding, the issuer withheld 6,448 shares at an indicated per-share tax withholding price of $2.19, leaving 105,409 shares reported as beneficially owned after the withholding.
Table II shows RSU activity: 3,907 and 8,790 RSUs were reported as vested under two grants, representing underlying common stock amounts reflected in the filing. The reporting person signed the Form 4 on 09/04/2025.
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), reported equity changes on 09/02/2025. Restricted stock units (RSUs) vested that day, resulting in the acquisition of 12,306 common shares (recorded as Code M) at no cash price. To satisfy mandatory tax withholding on the vesting, the issuer withheld 6,250 shares (recorded as Code F) at a price of $2.19 per share rather than an open-market sale, leaving 99,689 shares beneficially owned after the transactions. The filing also lists vested RSU components of 3,516 and 8,790 underlying common shares, with remaining RSU schedules described in the explanatory notes.
Iovance Biotherapeutics, Inc. (IOVA) submitted an 8-K reporting other events and provided a corporate presentation as an exhibit. The filing lists written and soliciting communications under Rule 425 and Rule 14a-12, plus pre-commencement communications under Rules 14d-2(b) and 13e-4(c). The disclosure includes Exhibit 99.1, a corporate presentation dated August 29, 2025, and an Inline XBRL cover page. The document is signed by Frederick G. Vogt, Ph.D., J.D. in his capacity as Interim CEO, President, and General Counsel.
Iovance Biotherapeutics, Inc. filed an 8-K reporting written and soliciting communications under several securities rules and that it has engaged Jefferies to use commercially reasonable efforts to sell the company’s common shares from time to time under customary trading parameters. The filing references pre-commencement and solicitation rules and states the communication is dated August 22, 2025. The 8-K is signed by Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel.
Iovance Biotherapeutics, Inc. filed a prospectus supplement to sell up to $350.0 million of common stock through an amended at-the-market sales agreement with Jefferies LLC. The agreement replaces the prior June 16, 2023 arrangement and allows sales from time to time, with Jefferies acting as agent and receiving up to 3% of gross proceeds. The company noted its common stock traded at $2.60 per share on August 19, 2025, and estimated up to 476.5 million shares outstanding assuming sale of 134.6 million shares at $2.60. Proceeds are intended to fund the commercial launch of Amtagvi, ongoing and planned clinical trials including IOV-LUN-202 and TILVANCE-301, pipeline development, and general corporate purposes. The prospectus highlights dilution risks, potential market price volatility from resale, indemnification to Jefferies, and forward-looking risks related to clinical, regulatory, manufacturing and financing uncertainties.